Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 13/2022

25.07.2022 | Original Article

Usefulness of 18F-FPP-RGD2 PET in pathophysiological evaluation of lung fibrosis using a bleomycin-induced rat model

verfasst von: Shuichi Hiroyama, Keiko Matsunaga, Miwa Ito, Hitoshi Iimori, Minako Tajiri, Yoshiyuki Nakano, Eku Shimosegawa, Kohji Abe

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Integrins αv are key molecules in the pathogenesis of fibrosis in multiple organs. To assess the potential utility of integrin αvβ3 imaging for idiopathic pulmonary fibrosis (IPF), we evaluated an 18F-FPP-RGD2 PET probe in a rat model of bleomycin-induced lung fibrosis.

Methods

Pulmonary fibrosis was induced by single intratracheal instillation of bleomycin (3 mg/rat). Positron emission tomography (PET)/computerized tomography scans were performed 4 weeks after bleomycin administration using 18F-FPP-RGD2. Total distribution volume (VT) was estimated using one-tissue/two-compartment, two-tissue/three-compartment models, and Logan graphical analysis (Logan plot; t* = 30 min). Plasma-free fractions were estimated from images of the left ventricle. Correlation between Logan VT and lung pathology was assessed by Spearman’s rank correlation.

Results

Histopathological evaluation demonstrated the development of fibrosis in IPF-model group. Integrin αv protein expression and lung radioactivity were higher in IPF-model group compared with control group. The lung radioactivity of 18F-FPP-RGD2 rapidly reached the peak after administration and then gradually decreased, whereas left ventricular radioactivity rapidly disappeared. Logan graphical analysis was found to be suitable for 18F-FPP-RGD2 kinetic analysis in the IPF-model lung. Logan VT values for 18F-FPP-RGD2 were significantly higher in IPF rats compared with control rats and strongly correlated with lung fibrosis, pathology, integrin αv protein expression, and oxygen partial pressure.

Conclusion

Our findings demonstrate that the integrin αvβ3 PET probe 18F-FPP-RGD2 can detect pathophysiological changes in lungs, including fibrosis accompanying upregulated integrin αv of IPF-model rats. These findings support the utility of 18F-FPP-RGD2 PET imaging for the pathophysiological evaluation of pulmonary fibrosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax Thorax. 2006;61:980–5.CrossRef
2.
Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J Eur Respir J. 2015;45:1382–92.CrossRef
3.
Raghu G. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. Eur Respir Rev. Eur Respir Rev. 2017;26
4.
Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States 2000 to 2011. Am J Respir Crit Care Med. 2016;193:1161–7. CrossRef
5.
Souza CA, Müller NL, Flint J, Wright JL, Churg A. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol. 2005;185:1531–9.
6.
Hunninghake GW, Bridget Zimmerman M, Schwartz DA, King TE, Lynch J, Hegele R, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193–6. CrossRef
7.
Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, et al. Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging: Springer; 2019.
8.
Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, et al. Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis 2019 101. Nat Commun. 2019;101(10):1–18 (Nature Publishing Group).
9.
Wuyts WA, Wijsenbeek M, Bondue B, Bouros D, Bresser P, RobaloCordeiro C, et al. Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration. 2020;99:73 (Karger Publishers).CrossRef
10.
Goodwin A, Jenkins G. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans. 2009;37:849–54. CrossRef
11.
Henderson NC, Sheppard D. Integrin-mediated regulation of TGFβ in fibrosis. Biochim Biophys Acta. 2013;1832:891–6.
12.
Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al. Visualisation of interstitial lung disease by molecular imaging of integrin α v β 3 and somatostatin receptor 2. Ann Rheum Dis. 2019;78:218–27.CrossRef
13.
Horan GS, Wood S, Ona V, Dan JL, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177:56–65. CrossRef
14.
Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol Am J Pathol. 2009;174:1264–79.CrossRef
15.
John AE, Luckett JC, Tatler AL, Awais RO, Desai A, Habgood A, et al. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med J Nucl Med. 2013;54:2146–52.CrossRef
16.
Guo N, Lang L, Li W, Kiesewetter DO, Gao H, Niu G, et al. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2 [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS One. 2012;7:37506–14.
17.
Hiroyama S, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, et al. Quantitative evaluation of hepatic integrin αvβ3 expression by positron emission tomography imaging using 18F-FPP-RGD2 in rats with non-alcoholic steatohepatitis. EJNMMI Res. 2020;10:118–29.
18.
Kapp TG, Rechenmacher F, Neubauer S, Maltsev OV, Cavalcanti-Adam EA, Zarka R, et al. A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins. Sci Rep. 2017;7:39805–17.
19.
Haskali MB, Roselt PD, Karas JA, Noonan W, Wichmann CW, Katsifis A, et al. One-step radiosynthesis of 4-nitrophenyl 2-[(18) F]fluoropropionate ([(18) F]NFP); improved preparation of radiolabeled peptides for PET imaging. J Labelled Comp Radiopharm. 2013;56:726–30. CrossRef
20.
Jin ZH, Furukawa T, Sogawa C, Claron M, Aung W, Tsuji AB, et al. PET imaging and biodistribution analysis of the effects of succinylated gelatin combined with l-lysine on renal uptake and retention of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in vivo. Eur J Pharm Biopharm Elsevier. 2014;86:478–86. CrossRef
21.
Bergeron M, Cadorette J, Tétrault MA, Beaudoin JF, Leroux JD, Fontaine R, et al. Imaging performance of LabPET APD-based digital PET scanners for pre-clinical research. Phys Med Biol Phys Med Biol. 2014;59:661–78. CrossRef
22.
Holman BF, Cuplov V, Millner L, Hutton BF, Maher TM, Groves AM, et al. Improved correction for the tissue fraction effect in lung PET / CT imaging. Phys Med Biol IOP Publishing. 2015;60:7387–402. CrossRef
23.
Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: Preliminary findings. Eur J Nucl Med Mol Imaging Springer. 2011;38:2238–46. CrossRef
24.
Akaike H. A New Look at the Statistical Model Identification. IEEE Trans Autom Control Springer. 1974;19:716–23.CrossRef
25.
Persson IM, Pettersson NF, Liu J, Håkansson HF, Örbom A, Zandt RI, et al. Longitudinal imaging using pet/ct with collagen-i pet-tracer and mri for assessment of fibrotic and inflammatory lesions in a rat lung injury model. J Clin Med. 2020;9:1–21.
26.
Tashiro J, Elliot SJ, Gerth DJ, Xia X, Pereira-Simon S, Choi R, et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res Mosby. 2015;166:554–67.CrossRef
27.
Yousefi-Manesh H, Noori T, Asgardoon MH, Derakhshan MH, Tavangar SM, Sheibani M, et al. Protective effect of dapsone against bleomycin-induced lung fibrosis in rat. Exp Mol Pathol. 2022;124:104737–44.
28.
Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al. Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2. Ann Rheum Dis. 2019;78:218–27.CrossRef
29.
Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, et al. Clinical quantification of the integrin αvβ6 by [18 F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging. 2020;47:967–79.CrossRef
30.
Chu KA, Yeh CC, Kuo FH, Lin WR, Hsu CW, Chen TH, et al. Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly. Stem Cell Res Ther BioMed Central Ltd. 2020;11:1–14.
31.
Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, et al. [18 F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18 F]FDG PET/CT approach. Eur J Nucl Med Mol Imaging. 2021;48:3058–74.CrossRef
Metadaten
Titel
Usefulness of 18F-FPP-RGD2 PET in pathophysiological evaluation of lung fibrosis using a bleomycin-induced rat model
verfasst von
Shuichi Hiroyama
Keiko Matsunaga
Miwa Ito
Hitoshi Iimori
Minako Tajiri
Yoshiyuki Nakano
Eku Shimosegawa
Kohji Abe
Publikationsdatum
25.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05908-4

Weitere Artikel der Ausgabe 13/2022

European Journal of Nuclear Medicine and Molecular Imaging 13/2022 Zur Ausgabe

Original Article

Hetero-bivalent agents targeting FAP and PSMA

Original Article

Noninvasive photoacoustic computed tomography/ultrasound imaging to identify high-risk atherosclerotic plaques

Original Article

Feasibility of in vivo CAR T cells tracking using streptavidin–biotin-paired positron emission tomography

Original Article

[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates

Image of the Month

18F-FDG PET/CT findings of mesenchymal hamartoma of the liver in an adolescent

Original Article

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study